title: [Antiproliferative effect of silencing mTOR gene on MCL Jeko-1 cell line and its mechanism].
abstract: OBJECTIVE
  To investigate the effect of silencing mTOR gene by RNA interference on proliferation and apoptosis, and its mechanism on mantle cell lymphoma Jeko-1 cell Line.
  
  
  METHODS
  The hairpin-like oligonucleotide sequences targeting mTOR gene was designed and transfected into Jeko-1 cells by lipofectamine TM 2000. The mTOR mRNA and protein were detected by RQ-PCR and Western blot. Cell growth was determined by MTT. Cell apoptosis was analyzed by flow cytometry. The expressions of Bcl-2, Bax, procaspase-3, procaspase-9, P70S6K,and p-P70S6K were detected by Western blot.
  
  
  RESULTS
  mTOR mRNA was markedly suppressed by shRNA targeting mTOR. mTOR shRNA suppressed proliferation and induced cells apoptosis of Jeko-1 cells. The cell apoptotic rates were (36.62 ± 3.24)%, (2.58 ± 1.04)%, (1.24 ± 0.30)% respectively, in mTOR shRNA, Neg-shRNA and Blank with statistically significant difference among them (P<0.05). mTOR shRNA down-regulated the expressions of Bcl-2, proCaspase3, proCaspase9 and p-70S6K, up-regulated the expression of Bax.
  
  
  CONCLUSIONS
  Deplete of mTOR gene may be realized through inhibiting the Akt/mTOR signaling pathway to promote the cell apoptosis and inhibit cell growth in Jeko-1 cell line.
authors: Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian Province, China.
authors: Ruiji
authors: R
authors: Zheng
authors: Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian Province, China.
authors: Yiqun
authors: Y
authors: Huang
authors: Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian Province, China.
authors: Xudong
authors: X
authors: Ma
mesh_terms: D017209:Apoptosis; D053148:Caspase 3; D053453:Caspase 9; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation; D006801:Humans; D020522:Lymphoma, Mantle-Cell; D034622:RNA Interference; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases; D014162:Transfection
chemical_list: D012333:RNA, Messenger; D034741:RNA, Small Interfering; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; C505407:CASP3 protein, human; C506433:CASP9 protein, human; D053148:Caspase 3; D053453:Caspase 9
references: Genes Dev. 2004 Aug 15;18(16):1926-45
references: 15314020
references: Blood. 2006 Sep 1;108(5):1668-76
references: 16645163
references: Cancer Metastasis Rev. 2009 Dec;28(3-4):305-16
references: 20013032
references: Oncogene. 2006 Oct 16;25(48):6436-46
references: 17041628
references: Nat Rev Drug Discov. 2006 Aug;5(8):671-88
references: 16883305
references: J Clin Oncol. 2009 Feb 1;27(4):511-8
references: 19075279
references: Rev Recent Clin Trials. 2010 Sep;5(3):189-208
references: 20533896
references: Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50
references: 18166498
references: Nat Rev Cancer. 2009 Aug;9(8):550-62
references: 19629070
references: FASEB J. 2002 Jun;16(8):771-80
references: 12039858
references: Curr Cancer Drug Targets. 2009 Mar;9(2):237-49
references: 19275762